Punch biopsy

Biopsy

Report in 240Hrs

At Home

No Fasting Required

Details

Small core biopsy.

₹296₹423

30% OFF

Punch Biopsy - Comprehensive Medical Test Guide

Why is it done?
- Obtains a cylindrical tissue sample from the skin or mucous membranes for microscopic examination and diagnosis of skin diseases
- Diagnoses suspicious skin lesions including suspected melanoma, basal cell carcinoma, squamous cell carcinoma, and other malignancies
- Evaluates chronic or persistent dermatologic conditions such as psoriasis, lichen planus, pemphigus, and systemic lupus erythematosus
- Assesses infectious skin conditions including fungal infections, bacterial infections, and viral lesions
- Evaluates inflammatory or bullous skin disorders when clinical diagnosis is uncertain
- Performed immediately upon clinical suspicion of skin malignancy or when lesions do not respond to standard treatment
Normal Range
- Normal/Negative Result: Tissue shows normal histological architecture consistent with the sampled anatomical site; no evidence of malignancy, infection, or inflammatory disease
- Pathology Interpretation: Results are typically classified as benign, suspicious for malignancy (dysplasia), or malignant; not reported as numerical values but as descriptive pathological diagnoses
- Interpretation Scale: Benign pathology indicates normal or non-cancerous findings; Atypical or dysplastic findings suggest possible precancerous changes; Malignant findings confirm skin cancer diagnosis
- Units of Measurement: Histopathological assessment is qualitative; tissue specimen typically 4-6mm in diameter and 4-8mm deep
- Normal vs Abnormal: Normal findings show regular cellular architecture with appropriate layers and no concerning features; abnormal findings include irregular cells, increased mitotic activity, loss of normal stratification, or evidence of malignancy
Interpretation
- Benign Findings: Indicates normal skin histology; may identify specific benign conditions such as common nevi, seborrheic keratosis, dermatofibroma, or inflammatory conditions; no further oncologic intervention required but clinical monitoring may continue
- Dysplastic/Atypical Findings: Indicates cellular atypia and possible precancerous changes; may include dysplastic nevi or actinic keratosis; suggests need for close follow-up, possible re-excision, or heightened surveillance protocols
- Malignant Findings: Confirms skin cancer diagnosis (melanoma, basal cell carcinoma, squamous cell carcinoma, or other malignancies); requires immediate staged surgical excision, possible imaging studies, and oncologic consultation
- Infectious Findings: Identifies fungal (PAS stain positive), bacterial, or viral organisms; directs targeted antimicrobial therapy; results may include culture and sensitivity testing
- Inflammatory Conditions: Identifies specific inflammatory or immunologic conditions such as pemphigus, pemphigoid, lupus erythematosus, or psoriasis; may require immunofluorescence staining for definitive diagnosis
- Affecting Factors: Specimen quality, adequate depth of biopsy, proper fixation, sampling of lesion center, patient sun exposure history, prior treatments (cryotherapy, chemotherapy), and pathologist expertise influence interpretation accuracy
Associated Organs
- Primary Organ System: Integumentary system (skin, hair follicles, sebaceous glands, sweat glands); may also evaluate mucous membranes and lips
- Malignancies Associated with Abnormal Results: Melanoma (risk of metastasis to lymph nodes, lungs, liver, and brain); basal cell carcinoma and squamous cell carcinoma (localized but with invasive potential); merkel cell carcinoma; cutaneous lymphoma
- Common Diseases Identified: Psoriasis, lichen planus, vitiligo, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, discoid lupus erythematosus, granuloma annulare, and various infectious dermatoses
- Complications and Risks: Bleeding and hematoma formation; infection at biopsy site; scarring and hypopigmentation; allergic reaction to anesthesia or antiseptic; nerve or vessel injury; incomplete lesion removal in malignancies requiring wider excision; delayed wound healing in immunocompromised patients
- Systemic Disease Association: Skin biopsy may reveal manifestations of systemic conditions such as sarcoidosis, amyloidosis, lymphoproliferative disorders, or cutaneous manifestations of internal malignancies
Follow-up Tests
- For Confirmed Malignancy: Wide local excision with appropriate margins based on tumor type and depth; sentinel lymph node biopsy for intermediate to high-risk melanomas; staging imaging (CT, MRI, PET scan); genetic testing for BRAF mutations in melanoma; immunohistochemistry and molecular testing as indicated
- For Dysplastic Findings: Complete excision of lesion with wider margins; dermatologic surveillance every 3-6 months; full body skin examinations; photographic documentation of nevi; consideration of dermoscopy for monitoring
- For Infectious Diagnosis: Fungal or bacterial culture and sensitivity; repeat biopsy if treatment fails; serologic testing for systemic infections if indicated; imaging studies if disseminated disease suspected
- For Inflammatory/Autoimmune Conditions: Direct and indirect immunofluorescence testing; systemic workup including ANA, anti-dsDNA, complement levels; gastrointestinal evaluation if pemphigus; ophthalmologic examination if systemic lupus involvement
- Monitoring Frequency: High-risk melanoma: every 3-6 months for years 1-2, then every 3-12 months; melanoma in situ or low-risk: annual monitoring; non-melanoma skin cancer: surveillance based on subtype and stage; chronic inflammatory conditions: periodic reassessment and treatment adjustment
- Complementary Diagnostic Tests: Dermoscopy for evaluation of pigmented lesions; reflectance confocal microscopy; optical coherence tomography; repeat punch or excisional biopsy for better margins and deeper sampling; immunohistochemistry panels for tumor classification
Fasting Required?
- Fasting Required: No - punch biopsy is a minimally invasive outpatient procedure that does not require fasting
- Medications to Avoid: Aspirin and NSAIDs should be discontinued 3-5 days prior to procedure to reduce bleeding risk; anticoagulants (warfarin, dabigatran, apixaban) require special consideration and may need temporary discontinuation based on indication; continue other routine medications as prescribed
- Patient Preparation Requirements: Wash biopsy site with gentle soap and water the morning of procedure; avoid applying lotions, cosmetics, or deodorants; wear loose, comfortable clothing; arrange transportation if sedation used (rarely); inform provider of keloid history, bleeding disorders, or allergies
- Anesthesia and Procedure Details: Local anesthesia (lidocaine 1-2% with or without epinephrine) administered via injection; procedure typically painless after anesthesia; takes 10-15 minutes; no need for NPO (nothing by mouth) status; may eat and drink normally before and after
- Post-Procedure Care Instructions: Keep wound clean and dry for 24 hours; apply antibiotic ointment as directed; change dressing daily; avoid strenuous activity and swimming for 5-7 days; keep sutures dry until removal (typically 7-14 days depending on location); watch for signs of infection (increasing redness, warmth, pus, fever)

How our test process works!